Evan Greebel acted as outside counsel for pharma company Retrophin from 2012 to 2014. Prosecutors alleged during that time Greebel assisted Martin Shkreli in using Retrophin’s assets to pay investors in unrelated hedge funds run by Shkreli through the use of phony settlement and consulting agreements.
Martin Shkreli looked uncharacteristically somber during his perp walk on Thursday morning. Begs the question: Is this the end of Shkreli's ludicrous, smug antics? Nah.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
This acquisition is a logical fit for Ligand, as OMT will add a slew of monoclonal antibody therapeutics to its small molecule-dominant pipeline.
However, U.S. Attorney Robert Capers says the investigation doesn't involve Martin Shkreli's price hike of Daraprim, and he's "not aware of where he got the funds for the Wu Tang album."
For people who hate Shkreli for what he's done in 2015, this will be like the government getting Al Capone for tax evasion.